سعر اكسجيد 500 مجم 28 قرص 2026

Deferasirox 500 mg dispersible tablets (tablets for oral suspension), 28 tablets per pack (Novartis); oral iron chelator.

• Treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in patients 2 years of age and older.Population: Patients ≥2 yearsDailyMed (U.S. National Library of Medicine)
• Treatment of chronic iron overload in patients 10 years and older with non-transfusion-dependent thalassaemia (NTDT) syndromes, liver iron concentration ≥5 mg Fe/g dry weight and serum ferritin >300 mcg/L.Population: Patients ≥10 years with NTDTDailyMed (U.S. National Library of Medicine)

• Most frequent (>5%) in transfusional iron overload: diarrhoea, vomiting, nausea, abdominal pain, skin rash and increased serum creatinine; in NTDT: diarrhoea, rash and nausea.International label, same product · DailyMed (U.S. National Library of Medicine)

• Estimated GFR <40 mL/min/1.73 m2; poor performance status; high-risk myelodysplastic syndromes; advanced malignancies; platelet count <50 x 10^9/L; known hypersensitivity to deferasirox or any component.International label, same product · DailyMed (U.S. National Library of Medicine)

• Boxed warning: may cause acute renal failure (sometimes fatal), hepatic failure (sometimes fatal) and gastrointestinal haemorrhage (sometimes fatal), particularly in elderly patients and those with advanced haematological disorders, comorbidities or low platelet counts.International label, same product · DailyMed (U.S. National Library of Medicine)
• Bone marrow suppression (neutropenia, agranulocytosis, worsening anaemia, thrombocytopenia), hypersensitivity, severe skin reactions, auditory and ocular disturbances and overchelation have been reported.International label, same product · DailyMed (U.S. National Library of Medicine)

• Aluminium-containing antacidsDo not take together with aluminium-containing antacid preparations.DailyMed (U.S. National Library of Medicine)
• CYP3A4 substrates (e.g. ciclosporin, simvastatin, hormonal contraceptives, midazolam)Deferasirox may induce CYP3A4 and reduce concentrations of CYP3A4 substrates; monitor for reduced effectiveness.DailyMed (U.S. National Library of Medicine)
• CYP2C8 substrates (e.g. repaglinide, paclitaxel)Deferasirox inhibits CYP2C8 and increases substrate concentrations; consider reducing repaglinide dose and monitor glucose.DailyMed (U.S. National Library of Medicine)

• No studies in pregnant women; in rats, deferasirox decreased offspring viability and increased renal anomalies in male offspring; use in pregnancy only if the potential benefit justifies the potential risk to the fetus.International label, same product · DailyMed (U.S. National Library of Medicine)
• No human milk data; deferasirox and metabolites are excreted in rat milk; decide whether to discontinue breastfeeding or the drug.International label, same product · DailyMed (U.S. National Library of Medicine)

• Deferasirox: Orally active chelator selective for iron (Fe3+); a tridentate ligand that binds iron with high affinity in a 2:1 ratio (US label).